Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GCG | P01275 | 3/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.34 |
| ▸ | GCGR | P47871 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | S100A4 | P26447 | 1/20 | 0.32 |
| ▸ | FABP3 | P05413 | 2/20 | 0.32 |
| ▸ | FABP4 | P15090 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036249 | 0.91 | GCGR (0.35) | PPARDPPARASMN1; SMN2DGAT1HPGD | |
| SCHEMBL6036211 | 0.89 | GCG (0.35) | PPARDPPARAGCGGCGRS100A4 | |
| SCHEMBL6035374 | 0.88 | GCGR (0.37) | PPARDPPARAKDM4EDGAT1GCG | |
| SCHEMBL6035777 | 0.86 | SMN1; SMN2 (0.37) | PPARDPPARASMN1; SMN2KDM4EHPGD | |
| SCHEMBL1633424 | 0.84 | SMN1; SMN2 (0.37) | PPARDPPARASMN1; SMN2KDM4EDGAT1 | |
| SCHEMBL6035372 | 0.82 | PPARD (0.36) | PPARDPPARASMN1; SMN2KDM4EDGAT1 | |
| SCHEMBL6036044 | 0.81 | SMN1; SMN2 (0.37) | PPARDPPARASMN1; SMN2KDM4EHPGD | |
| SCHEMBL6035388 | 0.81 | SMN1; SMN2 (0.37) | PPARDPPARASMN1; SMN2KDM4EDGAT1 | |
| SCHEMBL6036233 | 0.79 | GCGR (0.38) | PPARDPPARADGAT1GCGHCRTR1 | |
| SCHEMBL1633062 | 0.78 | PPARG (0.41) | PPARDPPARASMN1; SMN2KDM4EGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PPARD 2488/4885PPARA 1717/4885SMN1; SMN2 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.